New antibody tested for Tough-to-Treat blood cancers
NCT ID NCT05822843
Summary
This early-stage study tested a new antibody drug called ESG206 in adults with advanced B-cell cancers that had stopped responding to standard treatments. The main goal was to find a safe dose by giving small groups of patients increasing amounts of the drug and closely monitoring for side effects. Researchers also looked for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.